-
1.发明授权Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure 失效用于估计环形分子和包含环状结构的分子的一部分的三维形状的计算机实现的过程和计算机系统
公开(公告)号：US5619421A
公开(公告)日：1997-04-08
申请号：US261166
申请日：1994-06-17
申请人： Ganesh Venkataraman , Viswanathan Sasisekharan , Ram Sasisekharan , Ratnaleela Bobba , Charles L. Cooney , Robert Langer
发明人： Ganesh Venkataraman , Viswanathan Sasisekharan , Ram Sasisekharan , Ratnaleela Bobba , Charles L. Cooney , Robert Langer
CPC分类号： C07K1/00 , G06F19/704
摘要： A computer-implemented process determines candidate three-dimensional shapes of ring-shaped molecules through an exhaustive search of combinations of torsion angles of the bonds of the ring, given known bond lengths and bond angles for the bonds between atoms of the rings, a range of torsion angles and a resolution. Candidate combinations of the torsion angles are selected according to the range and resolution and coordinates of the atoms of the ring are determined for each candidate combination. It is then determined whether each candidate combination defines a physically possible ring. Indications of such candidate combinations are recorded. Candidate combination may then be selected from those recorded so that coordinates of atoms in candidate repetitive structures may be determined.
摘要翻译： 计算机实现的过程通过详细搜索环的键的扭转角的组合来确定环形分子的候选三维形状，给定已知的键长度和环的原子之间的键的键角，范围 的扭转角和分辨率。 根据范围和分辨率选择扭转角的候选组合，并且为每个候选组合确定环的原子的坐标。 然后确定每个候选组合是否定义了物理上可能的环。 记录这种候选组合的适应症。 然后可以从所记录的候选组合中选择候选组合，从而可以确定候选重复结构中原子的坐标。
-
公开(公告)号：US06217863B1
公开(公告)日：2001-04-17
申请号：US09066481
申请日：1999-01-19
申请人： Ranganathan Godavarti , Ram Sasisekharan , Steffen Ernst , Ganesh Venkataraman , Charles L. Cooney , Robert Langer
发明人： Ranganathan Godavarti , Ram Sasisekharan , Steffen Ernst , Ganesh Venkataraman , Charles L. Cooney , Robert Langer
IPC分类号： A61K3851
摘要： Modified heparinases having altered binding specificity and activity are provided. Isolated nucleic acids encoding the same as as vectors and host cells are provided. Methods for using the modified heparinases are also provided.
摘要翻译： 提供具有改变的结合特异性和活性的修饰的肝素酶。 提供编码与载体和宿主细胞相同的分离的核酸。 还提供了使用改性肝素酶的方法。
-
3.再颁专利公开(公告)号：USRE41328E1
公开(公告)日：2010-05-11
申请号：US12199215
申请日：2008-08-27
申请人： Ramnath Sasisekharan , Charles L. Cooney , Robert S. Langer , Daniel L. Lohse , Robert J. Linhardt
发明人： Ramnath Sasisekharan , Charles L. Cooney , Robert S. Langer , Daniel L. Lohse , Robert J. Linhardt
CPC分类号： C12N9/88 , Y10S435/822 , Y10S435/85
摘要： A purified heparinase I, II and III free of lyase activity and each having a molecular weight of 42,800 84,100, 70,800, respectively, are produced by culturing Flavobacterium heparinum. The kinetic properties of the heparinases have been determined as well as the conditions to optimize their activity and stability.
摘要翻译： 不含裂解酶活性的纯化肝素酶I，II和III分别通过培养肝炎黄杆菌而产生，分子量分别为42,400,84,100,70,800。 已经确定了肝素酶的动力学性质以及优化其活性和稳定性的条件。
-
公开(公告)号：US4678583A
公开(公告)日：1987-07-07
申请号：US873364
申请日：1986-06-12
CPC分类号： B01D11/0492 , C02F1/26 , C02F1/28 , C02F1/42 , C02F2101/30
摘要： A process for forming a purified solute from an aqueous solution is provided whereby a mixture of an extractant, a hydrate former and the aqueous solution is first formed. The hydrate former forms a hydrate with water while the solute does not form a hydrate. The extractant takes up the solute from the aqueous solution. The mixture is subjected to a temperature and pressure sufficient to form the solid hydrate of the hydrate former, an aqueous solution of the solute and a portion comprising the extractant containing the solute. The solute is recovered from the portion comprising the extractant and the solute.
摘要翻译： 提供从水溶液形成纯化溶质的方法，其中首先形成萃取剂，水合物形成剂和水溶液的混合物。 水合物形成与水的水合物，而溶质不形成水合物。 萃取剂从水溶液中吸收溶质。 使混合物经受足够的温度和压力以形成水合物形成剂的固体水合物，溶质的水溶液和包含含有溶质的萃取剂的部分。 从包含萃取剂和溶质的部分回收溶质。
-
公开(公告)号：US4341869A
公开(公告)日：1982-07-27
申请号：US180780
申请日：1980-08-25
CPC分类号： C12N9/88 , Y10S435/815 , Y10S435/85
摘要： Heparinase is produced by growing the bacteria, Flavobacterium heparinum, in a defined medium consisting of a carbon source, two or more amino acids and mineral salts in the absence of protein. Heparinase is recovered by batch chromatography of the cell extract from hydroxylapatite by elution with sodium chloride and sodium phosphate buffer washes.
摘要翻译： 肝素酶通过在不存在蛋白质的情况下在由碳源，两种或更多种氨基酸和矿物盐组成的限定培养基中生长细菌，肝素黄杆菌而产生。 通过用氯化钠和磷酸钠缓冲液洗涤洗脱，从羟基磷灰石的细胞提取物的间歇色谱法回收肝素酶。
-
公开(公告)号：US5567417A
公开(公告)日：1996-10-22
申请号：US431476
申请日：1995-05-01
申请人： Ramnath Sasisekharan , Marsha A. Moses , Matthew A. Nugent , Charles L. Cooney , Robert S. Langer
发明人： Ramnath Sasisekharan , Marsha A. Moses , Matthew A. Nugent , Charles L. Cooney , Robert S. Langer
IPC分类号： A61K47/30 , A61K35/74 , A61K38/00 , A61K38/46 , A61P9/00 , A61P17/00 , A61P27/02 , A61P35/00 , C12N9/88 , A61K38/51
摘要： Pharmaceutical compositions for delivering an effective dose to a desired site of a heparinase. These compositions are based on the discovery that heparinase alone can inhibit angiogenesis. The effective dosage is dependent not only on the heparinase, but also on the method and means of delivery, which can be localized or systemic. For example, in some applications, as in the treatment of psoriasis or diabetic retinopathy, the inhibitor is delivered in a topical ophthalmic carrier. In other applications, as in the treatment of solid tumors, the inhibitor is delivered by means of a biodegradable, polymeric implant.
摘要翻译： 用于将有效剂量递送至肝素酶的所需位点的药物组合物。 这些组合物基于单独的肝素酶可以抑制血管发生的发现。 有效剂量不仅取决于肝素酶，而且还取决于递送的方法和手段，其可以是局部的或全身性的。 例如，在一些应用中，如在牛皮癣或糖尿病性视网膜病变的治疗中，抑制剂在局部眼科载体中递送。 在其他应用中，如在实体瘤的治疗中，抑制剂通过可生物降解的聚合物植入物递送。
-
7.发明授权
公开(公告)号：US5389539A
公开(公告)日：1995-02-14
申请号：US983367
申请日：1992-11-30
申请人： Ramnath Sasisekharan , Daniel L. Lohse , Charles L. Cooney , Robert J. Linhardt , Robert S. Langer
发明人： Ramnath Sasisekharan , Daniel L. Lohse , Charles L. Cooney , Robert J. Linhardt , Robert S. Langer
IPC分类号： G01N33/573 , C07K16/40 , C12N9/88 , C12P19/26 , C12P21/08 , C12R1/20 , C12R1/91 , C12N9/00 , C12N1/20 , C12N9/52
CPC分类号： C12N9/88 , Y10S435/822 , Y10S435/85
摘要： A purified heparinase I, II and III free of lyase activity and each having a molecular weight of 42,800 84,100, 70,800, respectively, are produced by culturing Flavobacterium heparinum. The kinetic properties of the heparinases have been determined as well as the conditions to optimize their activity and stability.
摘要翻译： 不含裂解酶活性的纯化的肝素酶I，II和III分别通过培养肝素肝素而产生，分子量分别为42,600 84,100,70,800。 已经确定了肝素酶的动力学性质以及优化其活性和稳定性的条件。
-
公开(公告)号：US4830753A
公开(公告)日：1989-05-16
申请号：US34657
申请日：1987-04-10
IPC分类号： C12M1/12
摘要： In the membrane filtration of a liquid cell culture medium, superior flux rates and product recovery are obtained when a first charged particulate material and optionally a second charged particulate material bearing a charge opposite that of the first material are sequentially added to the medium prior to filtration.
摘要翻译： 在液体细胞培养基的膜过滤中，当在过滤之前将第一带电粒子材料和任选地带有与第一种材料的电荷相反的电荷的第二带电粒子物质依次加入到培养基中时，获得优异的通量率和产物回收率 。
-
公开(公告)号：US4396762A
公开(公告)日：1983-08-02
申请号：US295914
申请日：1981-08-24
CPC分类号： A61K31/715 , C08B37/0078 , Y10S435/85
摘要： There is disclosed a heparin product obtained by degradation of heparin with heparinase from Flavobacterium heparinum (ATCC 13125) or mutants thereof having activity to reduce the coagulation activity of factor X while not effecting the coagulation activity of thrombin.
摘要翻译： 公开了通过肝素从肝素黄素（ATCC13125）或其突变体用肝素酶降解获得的肝素产物，其具有降低因子X的凝血活性而不影响凝血酶凝血活性的活性。
-
10.再颁专利Purification, composition and specificity of Heparinase I, II, and III from Flavobacterium heparinum 有权来自肝炎黄杆菌的肝素酶I，II和III的纯化，组成和特异性公开(公告)号：USRE41461E1
公开(公告)日：2010-07-27
申请号：US12199157
申请日：2008-08-27
申请人： Daniel L. Lohse , Robert J. Linhardt , Ramnath Sasisekharan , Charles L. Cooney , Robert S. Langer
发明人： Daniel L. Lohse , Robert J. Linhardt , Ramnath Sasisekharan , Charles L. Cooney , Robert S. Langer
CPC分类号： C12N9/88 , Y10S435/822 , Y10S435/85
摘要： A single, reproducible scheme to simultaneously purify all three of the heparin lyases from F. heparinum to apparent homogeneity is disclosed herein. The kinetic properties of the heparin lyases have been determined as well as the conditions to optimize their activity and stability. Mono-clonal antibodies to the three heparinases are also described and are useful for detection, isolation and characterization of the heparinases.
摘要翻译： 本文公开了将来自肝素肝素的所有三种肝素裂解酶同时纯化到表观均一性的单一可再现方案。 已经确定了肝素裂解酶的动力学性质以及优化其活性和稳定性的条件。 还描述了对三种肝素酶的单克隆抗体，并且其可用于肝素酶的检测，分离和表征。
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.024 秒)
